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Abstract
Background: This study is aim to compare the clinical effectiveness between the two most prominent dry eye
disease (DED)-specific eye drops, 0.05% cyclosporine (CN) and 3% diquafosol (DQ).
Methods: This is a multi-centered, randomized, masked, prospective clinical study. A total of 153 DED patients were
randomly allocated to use CN twice per day or DQ six times daily. Cornea and conjunctival staining scores (NEI
scale), tear break-up time (TBUT), Schirmer test scores, and ocular surface disease index (OSDI) score were measured
at baseline, 4 and 12 weeks after treatment.
Results: At 12 weeks after treatment, NEI scaled scores were significantly reduced from the baseline by − 6.60 for
CN and − 6.63 for DQ group (all P < 0.0001, P = 0.9739 between groups). TBUT and Schirmer values for CN were
significantly improved from the baseline at 4 and 12 weeks (P = 0.0034, P < 0.0001 for TBUT, P = 0.0418, P = 0.0031
for Schirmer test). However, for DQ, TBUT showed significant improvement at 12 weeks only (P = 0.0281). Mean
OSDI score differences from the baseline to 12 weeks were improved by − 13.03 ± 19.63 for CN and − 16.11 ± 20.87
for DQ, respectively (all P < 0.0001, P = 0.854 between groups). Regarding drug compliance, the mean instillation
frequency of CN was less than that of DQ (P < 0.001). There were no statistically significant intergroup differences in
safety evaluation.
Conclusions: The level of improvement regarding NEI, TBUT, and OSDI scores were not significantly different
between the two treatment groups. However, with regards to the early improvement of TBUT and patient
compliance, patients using CN improved faster and with greater adherence to drug usage than did those treated
with DQ.
Trial registration: KCT0002180, retrospectively registered on 23 December 2016.
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Background
With the increase in the elderly population, dry eye dis-
ease (DED) is now the most common eye disease [1].
However, the exact prevalence of DED remains unknown.
It is estimated to be between 5 and 30% [1–3]. As numer-
ous clinical evidences cumulate, the awareness of DED
has risen considerably through mutual effort of many or-
ganizations. Recently, TFOS DEWS II provided the defin-
ition, classification, pathophysiology, and diagnostic
methodology on the basis of evidences [4–6]. Nonetheless,
DED still causes severe visual loss and complications, and
treatment is not easy. Despite hundreds of treatment regi-
mens, DED persists as a common concern.
Advances in our understanding of the risk factors, eti-
ology, and pathophysiology of DED have contributed to
an evolution in treatment strategies. In addition to the
classic artificial-tear formula, several types of anti-
inflammatory topical drugs and topical secretagogues
are now prescribed. Two decades ago, 0.05% cyclospor-
ine (Restasis®, Allergan Inc., Irvine, CA, USA) was intro-
duced; it is now the popular choice used worldwide for
cases with evidence levels I and II [7, 8]. Ophthalmolo-
gists in some countries have recently begun prescribing
3% diquafosol (Diquas®, Santen Pharmaceutical, Osaka,
Japan), a P2Y2-receptor agonist known to enhance
mucin and aqueous-humour production [9, 10]. The
secretogogue has been found to improve non-Sjögren
syndrome [10], postsurgical ocular discomfort [11],
Meibomian-gland dysfunction [12], and Sjögren syn-
drome [13]. However, due to the nationally regulated
limitation of the medications’ use, most clinicians are
not able to use both types of advanced topical DED
drugs. Although not same design as this study, there
have been a few previous comparative studies using both
drugs for dry eye treatment [14, 15]. Nonetheless, it has
been impossible for clinicians to make informed deci-
sions regarding the proper regimen for DED patients.
We performed this study at least to provide some per-
spective as to how DED patients can be treated.
The purpose of this single-blind, randomized, multi-
center study is to compare the clinical effectiveness, pa-
tient compliance, and side effects of the two most widely
used treatments (0.05% cyclosporine and 3% diquafosol)
for non-Sjögren dry-eye patients.
Methods
Informed consent was obtained from each patient prior
to participation in the study. The study was conducted
in accordance with the ethical principles specified in the
Declaration of Helsinki and Good Clinical Practice
Guidelines. It was approved by the institutional review
board (IRB) (IRB No: XC16MIMV0056S) before study
initiation. Because this study was conducted at multiple
clinical centers, IRB approval was acquired from each
center. Additionally, this trial was registered on the
Current Research Information System (CRIS) (http://
cris.nih.go.kr) and World Health Organization (WHO)
International Clinical Trials Registry Platform (ICTRP,
www.who.int/ictrp). The trial registration number is
KCT0002180.
Study design
This is a multicenter (12 centers), randomized,
evaluator-masked study. A total of 154 patients with
moderate DED who had received a screening test were
enrolled. The 153 eligible patients were randomly allo-
cated to receive 0.05% cyclosporine ophthalmic nanoe-
mulsion (CN group) or 3% diquafosol ophthalmic
solution (DQ group). After a 4-week washout period, pa-
tients in the CN group instilled 0.05% cyclosporine
(Cyporin N®; Taejoon Pharmaceutical Inc., Seoul, Korea)
twice daily and patients in the DQ group instilled 3%
diquafosol six times daily. To prevent bias from the dif-
ference in the total number of eye drops per day, pa-
tients in the CN group were asked to instill 0.15%
hyaluronic acid ophthalmic preparation (New Hyaluni®;
Taejoon Pharmaceutical Inc., Seoul, Korea) four times a
day. Both groups were allowed to instill it ad libitum
when they felt discomfort; they were told the total daily
number of instillations should not exceed six per day as
possible.
The patients were examined 4, 8, and 12 weeks after
the initiation of treatment. At 4 and 12 weeks after treat-
ment, both efficacy and safety were evaluated. At 8
weeks, only Ocular Surface Disease Index (OSDI) symp-
toms, adherence, and safety were evaluated.
Study population
Adult patients (age: ≥19 years) were eligible for partici-
pation if they had been diagnosed with moderate DED
according to the following criteria: (1) symptomatic dry
eye with complaint of ocular dryness, (2) cornea fluores-
cein staining ≥4 on the National Eye Institute (NEI)
scale, and (3) tear break-up time (TBUT) ≤ 10 s. Exclu-
sion criteria were as follows: (1) patients who had used
cyclosporine or diquafosol systemically or topically
within 4 weeks of the screening period; (2) patients who
had used topical agents to treat another ocular disease
(glaucoma, allergy, infection, etc.) within 4 weeks of the
screening period; (3) patients who had used any drug
that might influence the state of DED within 4 weeks of
the screening period; (4) patients with Sjögren syn-
drome; (5) patients who needed to use contact lenses
during the study period; (6) patients with an eyelid dis-
ease (e.g., trichiasis and entropion), or anterior ocular
disease (herpes keratitis, cicatricial pemphigoid, pteryg-
ium, neurotrophic keratitis, keratoconus etc.) and who
had undergone an ocular operation (punctal plug or
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nasolacrimal drainage process) within 4 weeks of the
screening period; and (7) patients with hypersensitivity
to drugs or patients who were pregnant.
Randomization
An independent statistical office (Seoul CRO, Co., Ltd.)
performed the permuted stratified block randomization
for sequence generation using SAS 9.2 (SAS institute
Inc., Cary, NC, USA), with participating centers as the
strata. The random sequence was sent to each center via
an interactive web-based response system (IWRS) to en-
sure allocation concealment during the full study period.
All medications were provided to patients after re-
packaging them in an aluminum pouch and container
box with coded product information. This was to main-
tain the masked condition, as the medications were of
different shapes and required different doses. Patients
were also prohibited from talking of drug-related topics
to efficacy evaluators; other designated study member(s)
assisted the patients with those things, including a pa-
tient diary.
Assessment of outcome measure
Efficacy assessment
The primary efficacy endpoint of this trial was defined
as the change in score on the NEI scale of corneal and
conjunctival staining from baseline to 12 weeks after
treatment. The secondary efficacy endpoints were de-
fined as the change in score on the NEI erosion scale,
Schirmer’s test value, TBUT, and OSDI scores at weeks
4 and 12. However, to determine satisfaction and adher-
ence, OSDI scores were measured at 8 weeks as well as
4 and 12 weeks. According to the National Eye Institute/
Industry Workshop report [16], corneal and conjunctival
staining was evaluated under a slit-lamp microscope
with a cobalt blue filter (scale: 0–33). The cornea was di-
vided into five sections: center, nasal, temporal, superior,
and inferior. While the patient blinked normally, 5 μL of
2% fluorescein solution was instilled in the conjunctival
sac. Fluorescein was scored based on 0 to 3 points of the
NEI scale at each section (scale from 0 to 15). Conjunc-
tiva was divided into six sections: three sections on the
nasal side and three sections on the temporal side. Then,
20 μL of 1% lissamine green solution was instilled in the
conjunctival sac. Conjunctival staining was evaluated
under low illumination and also scored based on 0 to 3
points of the NEI scale at each section (scale: 0–8).
For the TBUT, after corneal staining with 5 μL of 2%
fluorescein solution, the time between a normal blink
and the first appearance of a dry spot in the tear film
was measured. The average of three repeated measure-
ments was recorded. For the Schirmer’s test, the lacrimal
function, including physiologically basic and reflective
lacrimal secretion, was evaluated. Without anesthesia,
the Schirmer’s test strip was placed on the temporal
third of the lower eyelid between the lower palpebral
conjunctiva and the lower bulbar conjunctiva. After 5
min, the length of the tear fluid absorbed on the strip
was measured in millimeters.
To assess instillation adherence, all the patients were
instructed to record the number of drops they used of
the investigational drug and lubricant daily in a patient
diary and to bring their records on each visit. We
assessed and compared the satisfaction of these trial
drugs through a survey regarding the sensation of the
eye drops upon instillation scored on a 10-point visual
analog scale. The sensation was classified as overall satis-
faction, burning, stinging, blurring, stickiness, smooth-
ing, or moisturizing.
Safety assessment
The safety variable was the occurrence of adverse events
(AEs), determined during various visits based on phys-
ical signs and symptoms, an external eye examination,
slit-lamp microscopy, visual acuity, intraocular pressure,
and funduscopy.
Statistical analysis
Power analysis was performed to justify the number of
patients enrolled in the study. All statistical analyses
were performed using SAS 9.4 (SAS institute Inc., Cary,
NC, USA). The data were collected on both eyes treated
with the study drug, and, to evaluate efficacy, data on
the “worse” eye, defined as the eye with a worse baseline
corneal and conjunctival staining score, were included.
Data on both eyes were also included to evaluate safety.
In the case that both eyes had compatible baseline cor-
neal and conjunctival staining scores, the right eye was
used as the worse eye.
Descriptive statistics (mean ± standard deviation, min,
max) were used to summarize most efficacy data, includ-
ing the primary endpoint, corneal and conjunctival
staining, and frequency distribution for several categor-
ical variables (safety, instillation adherence). The Wil-
coxon signed-rank test was used to analyze within-group
changes. For intergroup comparisons, the Wilcoxon
rank-sum test was used. The general linear model
(GLM) was used to test the significance of each group,
time, and their interaction (group by time), where the
interaction between groups over time was the key out-
come (repeated measure ANOVA). For the assessment
of safety, intergroup differences were analyzed using a
Chi-square test.
The full analysis set (FAS) was defined as all random-
ized patients with the primary efficacy data; the per
protocol set (PPS) included all eligible patients without
major protocol deviations and with all efficacy data. The
PPS was the primary population for all efficacy analyses.
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The FAS was used for confirmatory purposes. The safety
set comprised all patients who, according to their patient
diary, received the study treatment at least once.
Results
The study design and patient selection are illustrated in
Fig. 1. A total of 153 patients who passed the screening
test were randomly assigned to each group (76 patients
in the CN group, 77 patients in the DQ group). To de-
termine drug safety, 144 patients (71 patients in CN; 73
patients in DQ) who instilled the assigned ophthalmic
solution at least once were asked if they had experienced
any adverse effects. The FAS, 125 patients who instilled
at least one dose of the received ophthalmic solution
and provided data for evaluating the primary efficacy
endpoint, included 62 patients in the CN group and 63
patients in the DQ group. The PPS, 115 patients who
completed the treatment, included 58 patients in the CN
group and 57 patients in the DQ group.
No statistically significant difference was observed be-
tween the groups in regard to sex, age, medical and sur-
gical history (within 6months), or present illness.
Additionally, there were no statistically significant differ-
ences observed between the groups in regard to the
staining scores, TBUT, Schirmer’s test scores, or OSDI
scores (Table 1).
Corneoconjunctival staining scores
The ocular surface NEI scores were significantly im-
proved 4 and 12 weeks after treatment. At 4 weeks, the
reduction of the corneal and conjunctival staining scores
from the baseline were − 4.74 ± 4.63 in the CN group
and − 4.04 ± 4.12 in the DQ group (p < 0.0001 from the
baseline, both groups). However, there was no statisti-
cally significant difference found between the two groups
in regard to corneal and conjunctival staining scores 4
weeks after treatment (Table 2) (p = 0.4860).
At 12 weeks, the primary end point of the study, the
mean change in the corneal and conjunctival staining
scores was − 6.60 ± 4.47 in the CN group and − 6.63 ±
4.72 in the DQ group (p = 0.9739, compared between
groups) (Table 2). Although both groups showed statisti-
cally significant improvements from the baseline (all p <
0.0001), there was no statistically significant difference
between the CN and DQ groups. When measured separ-
ately and compared serially, corneal erosion scores were
significantly improved in a time-dependent manner; the
value at 12 weeks was significantly different than the
value at 4 weeks in both groups (p < 0.001). The mean
conjunctival lissamine staining scores were also signifi-
cantly changed from the baseline. At 4 and 12 weeks
they were − 2.24 ± 3.40 and − 3.02 ± 3.38 in the CN group
and − 1.84 ± 2.93 and − 2.81 ± 3.47 in the DQ group, re-
spectively (all p < 0.0001).
Tear breakup time and Schirmer’s test score
The mean TBUT improved gradually over time in both
groups. The mean TBUT from baseline to weeks 4 and
12 were 0.77 ± 1.78 and 1.69 ± 2.45 in the CN group and
0.17 ± 1.95 and 0.73 ± 2.43 in the DQ group, respectively.
In the CN group, statistically significant improvements
were found 4 weeks after treatment (p = 0.0034) and 12
Fig. 1 Schematic illustration of the study design and patient selection. Safety set: the patients who received the assigned treatment at least once;
FAS: full analysis set, the patients who provided data for evaluating the primary efficacy; PPS: per protocol set, the patients who completed the
treatment without violation; CN: 0.05% cyclosporine nanoemulsion; DQ: 3% diquafosol
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weeks after treatment (p < 0.0001). However, in the DQ
group, a statistically significant improvement was ob-
served at 12 weeks only (p = 0.0281). The comparison of
TBUT in the CN and DQ groups showed no statistically
significant difference at the 4- or 12-week time points.
However, the CN group showed a tendency over time
toward better overall efficacy, and the difference between
the two groups was marginally significant (p = 0.0545)
(Table 3).
Changes in the mean Schirmer’s test score from the
baseline to 4 and 12 weeks were 0.83 ± 5.26 and 1.47 ±
6.20 in the CN group and 1.56 ± 5.45 and 1.06 ± 6.32 in
the DQ group, respectively. Compared to baseline, sta-
tistically significant improvements were observed at
week 4 in both groups (p = 0.0418 and p = 0.0168, re-
spectively). At week 12, the CN group showed Schir-
mer’s test scores significantly improved from the
baseline (p = 0.0031). In the DQ group, the mean Schir-
mer’s test score decreased from the 4-week score, and
marginal improvement from the baseline was observed
at week 12 (p = 0.0643). During the study period, no sta-
tistically significant between-group differences were
found (Table 4).
Mean changes in the OSDI score from the baseline to
weeks 4, 8, and 12 were − 11.88 ± 18.18, − 11.28 ± 17.60,
and − 13.03 ± 19.63 in the CN group and − 15.72 ± 15.85,
− 14.84 ± 19.58, and − 16.11 ± 20.87 in the DQ group, re-
spectively. Statistically significant improvements were
observed in all groups at weeks 4, 8, and 12 (all p <
0.0001). As with other parameters, there were no statisti-
cally significant differences found between the groups.
Drug-use pattern between groups
Because of the difference in the recommended frequency
of drop use, it was required for 100% adherence that the
mean instillation number was 6 times per day, as recom-
mended (2 instillations of the assigned medication plus
4 instillations of the lubricant in the CN group; 6 instil-
lations of the assigned medication in the DQ group). At
12 weeks, the mean adherence rates were 86.72 ± 22.97%
in the CN group and 110.72 ± 26.46% in the DQ group,
which indicates the instillation frequency of the CN
group was lower than that of the DQ group (p < 0.001)
(Fig. 2).
Safety evaluation
In the safety set, 8 AEs, including ocular pain, irritation,
foreign body sensation, and conjunctivitis, were reported
by 5 patients (3.47%): 5 AEs reported by 2 patients
(2.82%) in the CN group and 3 AEs reported by 3
Table 1 Baseline characteristics between CN and DQ groups
Mean ± SD (Range)
CN (n = 58) DQ (n = 57) p-value
Age (years) 47.21 ± 15.91 (24 ~ 81) 43.86 ± 16.74(22 ~ 79) 0.2594
Gender (M/F)a 6/52 7/50 0.7431
Corneoconjunctival staining (NEI scale) 10.78 ± 5.02 (4.00 ~ 27.00) 10.25 ± 4.89 (4.00 ~ 23.00) 0.5220
Corneal staining 5.47 ± 1.70 (4.00~10.00) 5.68 ± 1.84 (4.00 ~ 10.00) 0.5968
Conjunctival staining 5.31 ± 4.18 (0.00 ~ 18.00) 4.56 ± 3.71(0.00 ~ 15.00) 0.3089
TBUT (sec) 3.87 ± 1.32 (1.05 ~ 8.67) 4.29 ± 1.85 (0.50 ~ 8.42) 0.3459
Schirmer test (mm) 8.67 ± 6.30 (2.00 ~ 35.00) 7.96 ± 5.55 (1.00 ~ 30.00) 0.3955
OSDI (0–100) 43.36 ± 20.61 (8.00 ~ 94.00) 42.46 ± 18.90 (2.00 ~ 98.00) 0.8065
Comparison between CN and DQ groups by Wilcoxon rank sum test
CN 0.05% cyclosporin nanoemusion (0.5 mg/mL), DQ 3% diquafosol sodium (30mg/mL), SD standard deviation, TBUT tear break up time, OSDI ocular surface
disease index
aχ2 test
Table 2 Changes of Corneaconjunctival Staining Score (NEI score) between CN and DQ group














−6.60 ± 4.47 (−
22.00~3.00)
< 0.0001













0.5220 0.9708 0.3214 0.4860 0.9739
CN 0.05% cyclosporin nanoemusion (0.5 mg/mL), DQ 3% diquafosol sodium (30mg/mL)
aComparison between CN and DQ groups by Wilcoxon rank sum test
bComparison among three groups by Kruskal-Wallis test
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patients (4.11%) in the DQ group. All ocular AEs were
determined to be test-drug related. One AE in the DQ
group was moderately severe, and the rest were mild. All
of them were resolved. There were no statistically sig-
nificant intergroup differences (Table 5).
Systemically, 36 AEs were reported by 21 (14.58%) pa-
tients, including 21 AEs reported by 11 patients
(15.49%) in the CN group and 15 AEs reported by 10 pa-
tients (13.70%) in the DQ group. None of these were
confirmed to be test-drug related.
Discussion
In addition to artificial tear drops, cyclosporine and
diquafosol have been used for quite a long time, and
they are now used worldwide. However, with different
levels of approval and different insurance-
reimbursement policies in each country, few clinicians in
many countries are permitted to order both drugs.
Hence, most of these clinicians have experience with
only one of them. This study is meaningful because the
clinical effectiveness, safety, and side effects of both
drugs were compared in a controlled manner (in a ran-
domized, single-blind, and multicenter study) and a
novel cyclosporine nanoemulsion formulation was used.
According to the definition described in 2017 TFOS
DEWS II, dry eye is a multifactorial disease of the ocular
surface characterized by a loss of homeostasis of the tear
film accompanied by ocular symptoms, in which tear
film instability and hyperosmolarity, ocular surface in-
flammation and damage, and neurosensory
abnormalities play etiological roles. On the basis of this
concept, anti-inflammatory therapy such as cyclosporine
is now widely accepted by most clinicians who treat
DED patients. This study showed that the clinical effect-
iveness, drug compliance, and even side effects of both
cyclosporine and diquafosol were not significantly differ-
ent. In addition, both treatments were found to improve
the patients’ subjective symptoms, ocular surface ero-
sions, and TBUT until 12 weeks without significant dif-
ference. With the exception of patient compliance, the
effectiveness of the diquafosol was comparable to that of
cyclosporine at 4, 8, and 12 weeks after treatment. This
result means that the treatment effectiveness could be
similar if any pathophysiologic steps in DED are effect-
ively blocked. DED has a heterogeneous etiology and is
involved with several different hypothetically explainable
mechanisms [17, 18] and predisposing factors [5]. Add-
itionally, there are still questions relating to the core
mechanisms and initial step of DED [17–19]. Therefore,
whether by reducing ocular surface inflammation or im-
proving mucin secretion, both drug effects converge to
improve ocular surface dryness. Therefore, at least in the
short-term, the two drugs showed similar results. How-
ever, since DED is age dependent and may be a life-long
disease [1, 20], the long-term effectiveness and compli-
ance may differ between the drugs and should be inves-
tigated in the future.
The study also brings attention to the impact of hya-
luronic acid-containing artificial tear products, especially
in regard to their use with cyclosporine. Though
Table 3 Changes of TBUT values between CN and DQ group

















DQ 4.29 ± 1.85
(0.50~8.42)
4.46 ± 1.66 (0.73~8.67) 5.02 ± 1.85 (2.27~9.74) 0.17 ± 1.95
(−4.96~3.27)
0.73 ± 2.43 (−5.51~6.64) 0.0281
P
value
0.3459 0.7668 0.3033 0.7350 0.1521
CN 0.05% cyclosporin nanoemusion (0.5 mg/mL), DQ 3% diquafosol sodium (30mg/mL)
aComparison between CN and DQ groups by Wilcoxon rank sum test
bComparison among three groups by Kruskal-Wallis test
Table 4 Changes of Schirmer values between CN and DQ group




























0.3955 0.9754 0.3675 0.9214 0.8597
CN 0.05% cyclosporin nanoemusion (0.5 mg/mL), DQ 3% diquafosol sodium (30mg/mL)
aComparison between CN and DQ groups by Wilcoxon rank sum test
bComparison among three groups by Kruskal-Wallis test
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cyclosporine is a useful for the treatment of DED, most
patients feel they need to also use artificial tear drops, at
least in moderate or severe cases of DED. As cyclospor-
ine requires fewer doses than diquafosol, it seems to be
the better choice. In terms of artificial-tear usage, the
mean dose was 3.30 +/− 1.22 and 1.21+/− 1.60 in the
CN group and the DQ group, respectively. Together
with the artificial tear dosage, the total dosage was sig-
nificantly less in the CN group than in the DQ group
(5.20 +/− 1.38 and 6.64+/− 1.59, respectively; p < 0.0001).
Therefore, though cyclosporine may still require
artificial-tear usage, it may reduce the total number of
doses.
Other studies using cyclosporine for DED have added
the use of artificial tears. Lee [21] and Gong et al. [22]
reported that cyclosporine treatment groups used artifi-
cial tears to ensure effectiveness. Kim et al. reported that
a cyclosporine treatment group also used artificial tears
to reduce symptoms of Meibomian gland dysfunction
[23]. Diquafosol treatment groups also used artificial
tears to inhibit DED symptoms [11, 13, 23, 24]. In short,
neither cyclosporine nor diquafosol were solely adequate
for the treatment of moderate or severe DED. Proper
use of artificial tears may be needed in addition to cyclo-
sporine or diquafosol to ensure effectiveness.
In the present study, we used generic 0.05% cyclospor-
ine, not Restasis (Allergan Inc., Irvine, CA, USA). Be-
cause of the large molecular weight and hydrophobic
nature of cyclosporine [25, 26], its solubility in water is
poor (20–30 μg/mL) [27]. Restasis is a 0.05% cyclospor-
ine anionic emulsion formulation, of which the dispersed
particle size is relatively large and diversely distributed,
ranging from 50 nm to 1000 nm [26]. The fluid of the
emulsion is turbid, thermodynamically unstable, and
readily separates into two immiscible liquids. This re-
sults in flocculation, sedimentation, creaming, and co-
alescence [28]. To overcome the limitations of emulsion
formulation, nanoemulsion technology has been adopted
to develop the drug with a particle size ranging from 10
nm to 100 nm, providing optical transparency. Nanoe-
mulsion formulation is considered to be a thermo-
dynamically stable liquid dispersion resulting in
improved bioavailability and efficacy of lipophilic drugs
[29, 30].
Compared to the results of previous publications, the
generic form of cyclosporine showed results similar to
those of Restasis [31–33]. This may imply that the essen-
tial role of cyclosporine is more important than the ve-
hicle. However, direct comparison of different
cyclosporine preparations and Restasis is needed to de-
termine superiority.
There was a limitation to this study in that an
artificial-tear-only group was not included. As the pri-
mary purpose was to compare the effectiveness and su-
periority of cyclosporine and diquafosol, artificial tears
were used as a supplementary drug. There have been
many publications showing the improved treatment ef-
fect of both cyclosporine and diquafosol when used with
various artificial tears, which is why the artificial-tear-
only group was not included. Another limitation was
that the frequency of artificial-tear-drop use may affect
the results. Because of the dosing difference and rela-
tively severe cases, we allowed patients to use artificial
tears. Lastly, since the drugs have different action mech-
anisms, an additive or synergistic effect may result when
both drugs are used simultaneously. Further studies are
needed in this area. Considering the completely different
action mechanisms of the two drugs, each may be better
suited for the treatment of different DED subgroups.
The development of better diagnostic tools and methods
may help determine the subgroups that would benefit
from each medication.
Conclusions
We did not find a significant difference between the two
drugs in terms of subjective symptom improvement,
ocular surface erosion, or TBUT. Differences were noted
Fig. 2 Instillation adherence. Patients in both groups were asked to
instill drops 6 times per day: 2 times with cyclosporine plus 4 times
with hyaluronic acid in the 0.05% cyclosporine group (CN), and 6
times with diquafosol in the 3% diquafosol group (DQ). All patients
in both groups were allowed to instill hyaluronic acid ad libitum
when they felt discomfort and they were told the total daily number
of instillations should not exceed six per day as possible
Table 5 Local adverse effect of CN and DQ






Foreign body sensation 1 0
Erythema of eyelid 0 1
Total 6 5
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only in the patients’ compliance and in daily dosage.
Since the action mechanisms of the drugs are completely
different, and considering the wide range of causes lead-
ing to DED, specific target subgroups of DED patients
should be investigated for each drug.
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